Bring your biologic program to life with an end‑to‑end CRADS platform engineered for speed, scientific rigor, and regulatory confidence. Our team provides seamless transitions from early gene design through full clinical‑ready manufacturing.
Whether you’re advancing a first‑in‑class therapeutic or accelerating a biosimilar to market, we deliver robust, scalable, audit‑ready development that keeps your program moving—without compromises.
Why Partner With Us?
Decades of Proven Expertise
With over four decades of innovation across biologics and pharmaceuticals, we’ve supported hundreds of clients worldwide—from emerging biotech to global pharma leaders. Our team combines scientific depth with real‑world development experience to minimize risk and maximize success.
Complete Gene‑to‑Clinic Continuity
A fully integrated workflow ensures the smooth progression of every program:
Gene/clone → USP → DSP → analytics → formulation → tech transfer
- No handoffs.
- No delays.
- No friction.
Regulatory Strength You Can Trust
Our development is built on globally recognized quality systems. We operate in compliance with cGMP, GLP, and GCP standards, and have successfully undergone over 100 regulatory inspections and international audits by leading authorities, including the US FDA, WHO, MHRA, EMA, and others.
Flexible Bioproduction Platforms
To support diverse therapeutic modalities, we offer:
- Mammalian: CHO, HEK293
- Microbial: E. coli, Pichia pastoris
Delivering tailored solutions for molecules of all complexity levels.
